RALEIGH – Raleigh-headquartered Veranex, provider of technology-enabled product development services, has secured two new strategic partnerships with a private equity firm and an investment firm focused on health technology.
The firm, which focuses on product development for the medical technology industry, did not disclose the financial terms of the two latest strategic partnership deals.
“Veranex has built a robust platform that provides our customers with integrated, multidisciplinary medical technology product development services,” said David Dockhorn, CEO of Veranex, in a statement. “We are very well-positioned for further growth and continued impact.”
One deal is with Accelmed Partners II, a private equity firm. Uri Geiger, a managing partner at Accelmed, has joined the board of directors for Veranex.
The second deal is with Lauxera Capital Partners, and the co-founder of Lauxera, Samuel Levy, will join the board of directors of Veranex, as well.
“We are thrilled to welcome Accelmed and Lauxera to the Veranex team to help us continue building on this strong momentum,” said Dockhorn. “Each brings a wealth of experience that will support continued expansion of our geographic footprint, both operationally and commercially.”
More acquisitions coming?
Veranex formed in 2021 and has acquired six companies in that time period. That includes deals for Experien Group and IMMR.
The firm is backed by Summit Partners, who still retains majority ownership of Veranex, along with the Veranex management team, according to a statement.
Dockhorn said last year that the company will “continue building the platform organically and through acquisition in order to enhance our ability to help clients control costs and accelerate speed to market, all while mitigating development risk and delivering rapid global market viability assessments.”
According to its statement, Veranex provides design, engineering, regulatory, preclinical research, clinical development, commercial strategy, and market access services “on an integrated basis.”
Working with the firm yields faster speed to market, more cost-effective product development, with less risk, the statement noted.
Raleigh firm partners with global investor to provide ‘soup-to-nuts’ medtech services
